Dual checkpoint blockade in a neuroendocrine carcinoma with dual PD-L1/PD-L2 amplification and high tumor mutational burden

Jun Gong; Sandip Patel; Jacob J. Adashek; David Frishberg; Michelle Guan; Veronica R. Placencio-Hickok; Alexandra Gangi; Gillian Gresham; Richard Tuli; Young K. Chae; Razelle Kurzrock; Andrew E. Hendifar

doi:10.1200/PO.18.00391

Dual checkpoint blockade in a neuroendocrine carcinoma with dual PD-L1/PD-L2 amplification and high tumor mutational burden

Jun Gong, Sandip Patel, Jacob J. Adashek, David Frishberg, Michelle Guan, Veronica R. Placencio-Hickok, Alexandra Gangi, Gillian Gresham, Richard Tuli, Young K. Chae, Razelle Kurzrock, Andrew E. Hendifar^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	514-519
Number of pages	6
Journal	JCO Precision Oncology
Volume	2
DOIs	https://doi.org/10.1200/PO.18.00391
State	Published - 2018

ASJC Scopus subject areas

Cancer Research
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/PO.18.00391

Cite this

Gong, J., Patel, S., Adashek, J. J., Frishberg, D., Guan, M., Placencio-Hickok, V. R., Gangi, A., Gresham, G., Tuli, R., Chae, Y. K., Kurzrock, R., & Hendifar, A. E. (2018). Dual checkpoint blockade in a neuroendocrine carcinoma with dual PD-L1/PD-L2 amplification and high tumor mutational burden. JCO Precision Oncology, 2, 514-519. https://doi.org/10.1200/PO.18.00391

@article{61eccd5c9df0429f9dfc6a31c2a9cc10,

title = "Dual checkpoint blockade in a neuroendocrine carcinoma with dual PD-L1/PD-L2 amplification and high tumor mutational burden",

author = "Jun Gong and Sandip Patel and Adashek, {Jacob J.} and David Frishberg and Michelle Guan and Placencio-Hickok, {Veronica R.} and Alexandra Gangi and Gillian Gresham and Richard Tuli and Chae, {Young K.} and Razelle Kurzrock and Hendifar, {Andrew E.}",

note = "Funding Information: Supported by Southwest Oncology Group study S1609, which was supported by National Institutes of Health, National Cancer Institute (Grants No. CA180888 and CA180819); and in part by Bristol-Myers Squibb Company.",

year = "2018",

doi = "10.1200/PO.18.00391",

language = "English (US)",

volume = "2",

pages = "514--519",

journal = "JCO Precision Oncology",

issn = "2473-4284",

publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - Dual checkpoint blockade in a neuroendocrine carcinoma with dual PD-L1/PD-L2 amplification and high tumor mutational burden

AU - Gong, Jun

AU - Patel, Sandip

AU - Adashek, Jacob J.

AU - Frishberg, David

AU - Guan, Michelle

AU - Placencio-Hickok, Veronica R.

AU - Gangi, Alexandra

AU - Gresham, Gillian

AU - Tuli, Richard

AU - Chae, Young K.

AU - Kurzrock, Razelle

AU - Hendifar, Andrew E.

N1 - Funding Information: Supported by Southwest Oncology Group study S1609, which was supported by National Institutes of Health, National Cancer Institute (Grants No. CA180888 and CA180819); and in part by Bristol-Myers Squibb Company.

PY - 2018

Y1 - 2018

UR - http://www.scopus.com/inward/record.url?scp=85086177081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086177081&partnerID=8YFLogxK

U2 - 10.1200/PO.18.00391

DO - 10.1200/PO.18.00391

M3 - Article

C2 - 33215052

AN - SCOPUS:85086177081

SN - 2473-4284

VL - 2

SP - 514

EP - 519

JO - JCO Precision Oncology

JF - JCO Precision Oncology

ER -

Dual checkpoint blockade in a neuroendocrine carcinoma with dual PD-L1/PD-L2 amplification and high tumor mutational burden

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this